Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Clausen and colleagues describe novel glycosidases that convert group A, B and AB blood to universal O-type blood (p 454). Extension of this technology to use in transfusion medicine will depend on performance in clinical trials and regulatory approval. Credit: Photo Researchers, Inc.
The next wave of protein therapeutics, based on non-traditional scaffolds, may offer advantages in the range of conditions they can treat, delivery, and manufacturing. But they are just beginning to prove themselves in the clinic.
The UK's Office of Fair Trading is suggesting a system of drug pricing based on therapeutic value, which it believes would better focus innovation and investment toward creating more valuable drugs.
Last year marked the first time that erythropoietins were not the top-selling biotech drugs. Stacy Lawrence looks at the biopharmaceuticals that have usurped them.
Lack of recognition of the ethical, social and policy issues associated with the commercialization of neurotechnology could compromise new ventures in the area.
Other areas of biomedical research should emulate new standards from the International Society for Stem Cell Research highlighting the importance of sharing materials, data and research rights, and requiring fair global access to resulting diagnostics and therapies.
Characteristics of the complex and growing stem cell patent landscape indicate strategies by which public sector research institutions could improve the efficiency of intellectual property agreements and technology transfers in stem cells.
